Ceres Nanosciences reaches product development milestone for point-of-care Lyme disease test and closes on an additional $5.5M of Series A funding

Manassas, VA – May 31, 2018 – Ceres Nanosciences (Ceres) is announcing today that it has reached a key product development milestone for its Nanotrap® Lyme Antigen Test System. The Nanotrap® Lyme Antigen Test System will proceed into manufacturing and analytical performance testing this year and is on track for clinical study and FDA submission in 2019. “The Nanotrap® Lyme Antigen Test System presents a unique and powerful approach to dealing with Lyme disease. It will address the critical need for an accurate, direct test for early detection of a devastating disease and it will be available right in the...

Walking speeds of multiple sclerosis patients, as measured by the Echo5D Ambient Measurement System, showed strong agreement with two clinical “gold standards”

Atlas 5D is pleased to report that its Ambient Measurement System, Echo5D, produces similar results as two clinical gold standards of gait measurement in multiple sclerosis patients. The Echo5D allows for convenient in-home measurement. Walking speed is an important measure of gait impairment in multiple sclerosis (MS). The clinical assessment of walking speed requires dedicated time, space, and personnel, and may not accurately gauge real-world performance. The term “Ambient Measurement System” (AMS) refers to a new class of device that passively measures walking speed at home, without the need for dedicated space or specialized setup. This study compared an AMS,...

Atlas5D’s Ambient Measurement System (AMS), Echo5D, selected to support Solid Biosciences gene-transfer clinical trial

Atlas5D is proud to announce that Solid Biosciences will utilize the company’s 24×7 real-world mobility and behavioral measurements as part of “Ignite DMD”, a phase I/II gene transfer study to investigate the safety, tolerability, and efficacy of intravenous SGT-001 in patients with Duchenne muscular dystrophy (DMD). Atlas5D’s Ambient Measurement System (AMS), dubbed Echo5D, will be placed into each patient’s home to help quantify treatment response. Jorge Quiroz, MD, Chief Medical Officer of Solid Biosciences, said, “In the past, there has been no technology that could effectively measure clinically relevant movements in a person’s own home, without the requirement for wearables,...

BGI, Hummingbird Diagnostics to Develop miRNA Tests for Neurodegenerative Disorders

Dec 06, 2017 | staff reporter NEW YORK (GenomeWeb) – BGI of China and Hummingbird Diagnostics of Germany have signed a memorandum of understanding to collaborate on miRNA-based molecular diagnostic applications using next-generation sequencing technology, in particular in the areas of neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease. Under the agreement, the partners will use Hummingbird’s miRNA database and expertise in sample preparation as well as BGI’s BGISEQ sequencer and analysis pipeline to develop targeted miRNA in vitro diagnostic assays for Alzheimer’s, Parkinson’s, and other diseases. In addition, the firms will collaborate in the areas of wellness, fitness, and...

Ceres Nanosciences announces plans for significant growth in Prince William County, Virginia

Prince William County, VA – December 12, 2017 – Ceres Nanosciences (Ceres) is pleased to announce its recent expansion in Prince William County, Virginia. Following a successful fundraising round in 2017, Ceres has rapidly expanded both its staff and its facilities to accommodate the growing demand for the novel Nanotrap® particle platform across the life sciences industry. The Nanotrap® particle provides enhanced sample processing capabilities to new and existing diagnostic tests for some of the most challenging diseases and conditions, such as Lyme disease, respiratory diseases, emerging infectious diseases and cancer detection, as well as for improved health and wellness monitoring....

The Managers of GreyBird Ventures Partner with JF Healthcare in China

China, the world’s second largest and fastest growing market for healthcare products and services, cannot be ignored in the plans for any medical technology enterprise. It is a country where doing business as a foreign entity can be both highly complex and fraught with potential pitfalls. Therefore, the managers of GreyBird Ventures have decided to partner with a trusted enterprise, JiuFeng Healthcare (JF), to provide advice, assistance, and access to the Chinese market both for our firm and our portfolio companies. The GreyBird Managers have enjoyed a decades-long trustful relationship with the Founder, Chairman, and CEO of JF, Frank Wu...

GreyBird Ventures

is named after the arctic tern, a bird that migrates 71,000 km annually. As they can live for 30 years, this is the lifetime equivalent of three trips to the moon and back. Not bad for a 100 gram bird. We strive to emulate its size to performance ratio as well as its global reach.


For additional information, please contact: